- Home
- CAH vs TAK Comparison
CAH vs TAK Comparison
Compare CAH & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAH | TAK |
|---|---|---|
| Founded | 1979 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0B | 43.3B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | CAH | TAK |
|---|---|---|
| Price | $227.94 | $18.13 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $230.45 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | 0.89% | ★ 2.86% |
| EPS Growth | ★ 86.96 | N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $222,578,000,000.00 | N/A |
| Revenue This Year | $17.34 | $0.04 |
| Revenue Next Year | $8.95 | $0.92 |
| P/E Ratio | $122.23 | ★ $41.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $120.72 | $12.99 |
| 52 Week High | $233.60 | $18.82 |
Technical Indicators
Market Signals| Indicator | CAH | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 55.02 |
| Support Level | $206.07 | $14.78 |
| Resistance Level | $230.20 | $18.82 |
| Average True Range (ATR) | 5.11 | 0.23 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 71.86 | 46.92 |
Price Performance
Historical ComparisonAbout CAH Cardinal Health Inc.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.